Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 130

RNA Small Molecule Engineering Disease 130

Drug Discovery World

SEPTEMBER 4, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130

RNA Disease Research Drugs 130

Crown Bioscience

JULY 15, 2024

In the world of RNA analysis, researchers have an array of technologies at their disposal. In this post, we'll delve into three popular RNA analysis methods— transcriptome-wide RNA-Seq, Nanostring nCounter, and targeted RNA-Seq panels—comparing their features and discussing when to use each.

RNA 52

RNA Research 52

Drug Discovery World

JUNE 7, 2023

Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. The post Grant supports discovery of RNA-targeting Henipavirus therapeutics appeared first on Drug Discovery World (DDW). Evotec has received a $1.7

RNA 130

RNA Small Molecule Virus Vaccine 130

Drug Discovery World

SEPTEMBER 25, 2023

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?

RNA 130

RNA Disease Research Drugs 130

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. This landscape is rapidly changing.

RNA 130

RNA DNA Therapies Small Molecule 130

Drug Discovery World

SEPTEMBER 12, 2022

As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. The post New solution to boost RNA drug development appeared first on Drug Discovery World (DDW).

RNA 130

RNA Drug Development Vaccine Drugs 130

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . Using RNA interference, researchers restored the normal biological function of FKTN in patient-derived cells, offering hope for a new therapy. . Modifying RNA function.

RNA 130

RNA DNA Clinical Trials Therapies 130

Drug Discovery World

JANUARY 26, 2023

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.

RNA 130

RNA Small Molecule Engineering Disease 130

BioPharma Drive: Drug Pricing

MAY 23, 2024

After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

RNA 117

RNA 117

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The post RNA-based immunotherapy eradicates melanoma tumours appeared first on Drug Discovery World (DDW).

RNA 130

RNA Clinical Trials Research Trials 130

Drug Discovery World

JANUARY 10, 2023

This collaboration aims to further exploit circRNAs by developing a novel mechanism to facilitate RNA circularisation specifically in colorectal cancer cells. The post Alliance to develop circular RNA-based therapeutics appeared first on Drug Discovery World (DDW).

RNA 130

RNA Vaccine Therapies Drugs 130

Drug Discovery World

AUGUST 25, 2023

In this roundtable, moderated by DDW and sponsored by Azenta Life Sciences, you will learn about the biggest challenges related to the delivery of RNA therapeutics. Philip Cruz Dr Neill Liptrott Reece Armstrong Panellists will address the following questions: How has the Covid-19 pandemic influenced the advancement of RNA research?

RNA 130

RNA Science Disease Research 130

Chemical Biology and Drug Design

DECEMBER 13, 2023

This up-to-date commentary/perspective article sheds light on the revolutionary approaches designed to target the principal viral weapon “RNA” used by RNA viruses (e.g., the severe acute respiratory syndrome coronavirus 2 “SARS-CoV-2”) to infect humans and spread infections, the genomic RNA strands.

RNA 100

RNA Disease Virus Drugs 100

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . The post Biotech company raises $30M to target RNA modifying enzymes appeared first on Drug Discovery World (DDW).

RNA 130

RNA Immune Response Small Molecule Therapies 130

Science Daily: Pharmacology News

JUNE 24, 2024

Researchers have harnessed a bacterial immune defense system, known as CRISPR, to efficiently and precisely control the process of RNA splicing.

RNA 108

RNA Research Disease 108

Drug Discovery World

DECEMBER 5, 2022

LevitasBio will present how single-cell RNA sequencing has progressed the field of drug discovery and how upstream sample preparation methods that preserve cells in their native state is critical in identifying relevant biomarkers for drug discovery and development. This represents a huge loss for both industry and the advance of medicine.

RNA 130

RNA Drugs Clinical Trials Trials 130

BioPharma Drive: Drug Pricing

JUNE 18, 2024

While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.

RNA 67

RNA Drugs 67

Fierce BioTech

JULY 1, 2024

Streamlining the Path from Discovery to Patient – Simpler RNA Manufacturing with Aldevron’s Codex® HiCap RNA Polymerase swheeler Mon, 07/01/2024 - 17:17 Wed, 08/07/2024 - 10:00 Resource Type Webinar Kyle Studey, M.S. Codex ® is a trademark of Codexis, Inc. Listing Image aldevron 250x190.png

RNA 40

RNA Engineering Research 40

Drug Discovery World

DECEMBER 1, 2022

LevitasBio will present how single-cell RNA sequencing has progressed the field of drug discovery and how upstream sample preparation methods that preserve cells in their native state is critical in identifying relevant biomarkers for drug discovery and development. This represents a huge loss for both industry and the advance of medicine.

RNA 130

RNA Clinical Trials Drugs Trials 130

Drug Target Review

DECEMBER 6, 2023

Dear readers, RNA, or ribonucleic acid, plays a pivotal role in the intricate dance of cellular processes. We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.

RNA 52

RNA DNA Vaccine Science 52

Science Daily: Pharmacology News

SEPTEMBER 7, 2023

By adding synergistic self-adjuvanting properties to Covid-19 RNA vaccines, researchers showed they could significantly boost the immune response generated in mice.

RNA 86

RNA Vaccine Engineering Immune Response 86

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. The field is faced with a number of obstacles that require specifically assay technologies to surmount.

RNA 96

RNA Small Molecule Disease Assay Development 96

Science Daily: Pharmacology News

SEPTEMBER 19, 2023

A new study shows the isolation and sequencing of more than a century-old RNA molecules from a Tasmanian tiger specimen preserved at room temperature in a museum collection. This resulted in the reconstruction of skin and skeletal muscle transcriptomes from an extinct species for the first time.

RNA 88

RNA Virus International Research 88

SCIENMAG: Medicine & Health

AUGUST 14, 2023

A technique that enables scientists to record gene mutations and patterns of gene activity in individual cells has been extended to cover RNA splicing as well, in a study led by researchers at Weill Cornell Medicine, the New York Genome Center and the Princess Margaret Cancer Centre in Toronto.

RNA 83

RNA Disease Research 83

Drug Target Review

JANUARY 24, 2024

Scientists from Northwestern Medicine have demonstrated that RNA interference could have a crucial role in the onset and development of Alzheimer’s disease (AD). sRNAs Cellular functions rely on numerous protein-coding and noncoding RNAs and the RNA-binding proteins associated with them, which form ribonucleoprotein complexes (RNPs).

RNA 64

RNA Disease DNA Engineering 64

BioPharma Drive: Drug Pricing

APRIL 22, 2024

billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8

RNA 64

RNA Small Molecule Disease Research 64

BioPharma Drive: Drug Pricing

SEPTEMBER 5, 2023

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

RNA 70

RNA Therapies 70

Broad Institute

APRIL 4, 2024

A Practical guide to bulk RNA-seq, including guidelines for eQTL analysis By Rose Circeo April 4, 2024 Breadcrumb Home A Practical guide to bulk RNA-seq, including guidelines for eQTL analysis The Primer on Medical and Population Genetics is a series of weekly lectures on genetics topics related to human populations and disease.

RNA 52

RNA Bioethics Disease Research 52

Covalent Modifiers

FEBRUARY 25, 2024

TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA. Moreover, TD19 displays good anticancer efficacy in acute myeloid leukemia and glioblastoma multiforme cell lines.

RNA 78

RNA Cell Based Assays Regulations Research 78

BioPharma Drive: Drug Pricing

JANUARY 3, 2024

The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.

RNA 70

RNA Drugs 70

Drug Discovery World

MAY 21, 2024

Takara Bio has launched PrimeCap T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development. ” PrimeCap T7 RNA Polymerase is currently available in research grade, however, the company has announced plans to release a GMP version of the enzyme shortly.

Production 147

Production RNA Engineering Therapies 147

Drug Discovery World

MARCH 21, 2024

A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The technology has platform potential, as it leverages a universal small RNA pathway to target generic mRNA features.

RNA 130

RNA Molecular Biology Laboratories Engineering 130

Drug Discovery World

MARCH 7, 2024

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. JB Michel, CEO and co-founder of Patch Biosciences: “Joining Ginkgo Bioworks represents an exciting step in our journey to engineer better genetic medicines.

RNA 130

RNA Engineering Therapies Virus 130

Drug Discovery World

JULY 3, 2024

As a result, the data provides an important proof-of-concept for Circio’s circular RNA platform, which we expect will translate into improved gene therapies for patients in the future,” said Dr Thomas Hansen, CTO at Circio. “In This is a clear demonstration of a substantial, and statistically significant, advantage over mRNA-based expression.

RNA 147

RNA Protein Expression Therapies Drugs 147

Drug Discovery World

SEPTEMBER 28, 2023

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.

RNA 130

RNA Treatment Drug Development Production 130